Lakewood-Amedex

Approximately $10 Billion per annum in lost productivity, hospitalization and physicians costs, as well as loss of life in the US is due to the ~76 million cases of food-borne illnesses each year in the US, of which ~100,000 are caused by Shiga-toxin producing E. coli (STEC).  The industry has implemented a number of additional safeguards to protect the food chain, however; the number of outbreaks of food-related illness continues to increase.  Regardless of the continued promises of both industry and government supervision, the immense scale of the food industry ensures that consumers will always face some risk of contracting a potentially life threatening illness. 

Lakewood Amedex is developing therapeutics capable of binding deadly toxins produced by bacteria that cause severe illness and often fatalities.  In March 2007, Lakewood Amedex entered into an exclusive worldwide license agreement with Tufts University that granted it rights to a panel of fully human monoclonal antibodies developed against the exotoxins produced by Shiga-toxin producing Escherichia coli (STEC), particularly E.coli O157:H7.  This bacterial strain has been linked to many food borne infections throughout the world.  The monoclonal antibodies, developed in the lab of Dr Saul Tzipori, have been extensively tested for both their ability to neutralize toxin and protect against the effects of E.coli O157:H7 infection. The Company is currently developing a new high expressing manufacturing cell line for the lead monoclonal antibody which is anticipated to be completed in early 2012.  Lakewood Amedex is currently seeking a partner to help support the clinical development while it develops plans for producing a cGMP clinical lot for Phase I trials.